As I write this, it’s the evening before I start receiving Uplizna (inebilizumab-cdon) infusions, a preventive treatment for my neuromyelitis optica spectrum disorder (NMOSD). I’ll admit, I’m feeling anxious. Here’s how Uplizna works: Astrocytes are a type of cell that helps nerves work properly. On the surface of…
Uplizna (inebilizumab-cdon)
Uplizna (inebilizumab) reduces the number and size of subclinical lesions — those that cause no apparent symptoms — in the spinal cord of people with neuromyelitis optica spectrum disorder (NMOSD) about six months after the start of treatment. That’s according to a new analysis from the Phase…
Uplizna (inebilizumab) reduces the formation of asymptomatic lesions in the nerves that connect the eyes to the brain in people with neuromyelitis optica spectrum disorder (NMOSD), according to a new data analysis from the Phase 2/3 N-MOmentum trial. Asymptomatic, or subclinical, lesions are those that don’t lead to…
When I was diagnosed with neuromyelitis optica (NMO) in 2012, the U.S. Food and Drug Administration (FDA) hadn’t yet approved any medications specifically to treat this disease. However, doctors could select various therapies to help patients prevent or deal with attacks. When NMO patients had an attack, doctors treated…
Recent Posts
- Late-onset NMOSD responds better to newer, highly effective therapies
- New biomarker may help gauge disease severity in NMOSD
- The longest night of the year offers hope of brighter days with NMOSD
- Advanced plasma exchange therapy effectively eases NMOSD attacks
- Reaffirming that access to healthcare is a human right
- Brain, spinal cord shrinkage linked to distinct NMOSD outcomes: Study
- Reflecting on what I’m grateful for softens the edges of NMOSD
- When my invisible illness meets my very visible disabled parking spot
- Study IDs environmental factors tied globally to higher NMOSD risk
- Inflammatory protein S100A9 ID’d as new treatment target in NMOSD